{"filing":{"accession_number":"0001628280-26-053940","cik":"0001828185","ticker":"BRNS","company_name":"Barinthus Biotherapeutics plc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"brns-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1828185/000162828026053940/brns-20260806.htm"},"events":[{"id":25876,"run_id":23493,"accession_number":"0001628280-26-053940","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"The filing discloses Barinthus Bio's financial results for the quarter ended June 30, 2026, including cash position ($59.6M), R\u0026D expenses ($3.9M), G\u0026A expenses ($7.1M), and net loss ($10.6M or $(0.26) per share). The press release explicitly states \"Barinthus Biotherapeutics plc...today announced its financial results for the quarter ended June 30, 2026,\" which is the core disclosure under Item 2.02. While the filing also discusses the proposed Clywedog merger and clinical trial progress, the primary Item 2.02 content is the quarterly earnings announcement.","company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26810,"accession_number":"0001628280-26-053940","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses Barinthus Bio's financial results for the quarter ended June 30, 2026, including cash position ($59.6M), R\u0026D expenses ($3.9M), G\u0026A expenses ($7.1M), and net loss ($10.6M or $(0.26) per share). The press release explicitly states \"Barinthus Biotherapeutics plc...today announced its financial results for the quarter ended June 30, 2026,\" which is the core disclosure under Item 2.02. While the filing also discusses the proposed Clywedog merger and clinical trial progress, the primary Item 2.02 content is the quarterly earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:40:24.939682+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26810,"accession_number":"0001628280-26-053940","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses Barinthus Bio's financial results for the quarter ended June 30, 2026, including cash position ($59.6M), R\u0026D expenses ($3.9M), G\u0026A expenses ($7.1M), and net loss ($10.6M or $(0.26) per share). The press release explicitly states \"Barinthus Biotherapeutics plc...today announced its financial results for the quarter ended June 30, 2026,\" which is the core disclosure under Item 2.02. While the filing also discusses the proposed Clywedog merger and clinical trial progress, the primary Item 2.02 content is the quarterly earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:40:24.939682+00:00","company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","filing_date":"2026-08-06"}]}